Acute treatment of the headache phase of migraine attacks with or without aura in adults.
The FDA has approved IntelGenx/Gensco's rizatriptan benzoate (Rizafilm VersaFilm) oral thin film for acute migraine treatment through the 505(b)(2) new drug application (NDA) pathway
IntelGenx Corp has received a Complete Response Letter from the FDA regarding its resubmitted 505(b)(2) New Drug Application for Rizaport...
RedHill Biopharma Ltd. an Israeli biopharmaceutical company together with IntelGenx Corp., a Canadian drug delivery company have announced that they received...
IntelGenx Corp., a Canadian drug delivery company focusing on oral drug delivery, and RedHill Biopharma Ltd. , an Israeli biopharmaceutical...
The German Federal Institute for Drugs and Medical Devices (BfArM) has confirmed the positive outcome of the European Decentralized Procedure...